Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Th17 cells are restrained by Treg cells via the inhibition of interleukin‐6 in patients with rheumatoid arthritis responding to anti–tumor necrosis factor antibody therapy

McGovern, Jenny L., Nguyen, Dao X., Notley, Clare A., Mauri, Claudia, Isenberg, David A., Ehrenstein, Michael R. · 2012 · Arthritis & Rheumatism

Abstract

Objective: The importance of interleukin‐17 (IL‐17) is underscored both by its resistance to control by Treg cells and the propensity of Treg cells to produce this highly inflammatory cytokine. This study sought to address whether Th17 cells are inhibited by Treg cells in rheumatoid arthritis (RA) patients responding to anti–tumor necrosis factor (anti‐TNF) therapy, and if so defining the underlying mechanisms of suppression. Methods: Inhibition of Th17 cell responses was determined by Treg cell suppression assays. The Treg cell phenotype was analyzed using flow cytometry and enzyme‐linked immunosorbent assay. Mechanisms of suppression were tested by cytokine addition or antibody blockade. Results: Th17 responses were inhibited by Treg cells from RA patients responding to the anti‐TNF antibody adalimumab (Treg ada), but not by Treg cells from healthy individuals or patients with active RA. Furthermore, Treg ada cells secreted less IL‐17, even when exposed to proinflammatory monocytes from patients with active RA. Treg ada cells suppressed Th17 cells through the inhibition of monocyte‐derived IL‐6, but this effect was independent of IL‐10 and transforming growth factor β, which mediated the suppression of Th1 responses. Adalimumab therapy led to a reduction in retinoic acid receptor–related orphan nuclear receptor C–positive Th17 cells and an increase in FoxP3+ Treg cells lacking expression of the transcription factor Helios. However, this acquisition of IL‐17–suppressor function was not observed in RA patients responding to treatment with etanercept, a modified TNF receptor–Fc fusion protein. Indeed, there was no alteration in Treg cell number, function, or phenotype in etanercept‐treated patients, and Th17 responses remained unchecked. Conclusion: Th1 and Th17 responses are controlled through distinct mechanisms by Treg cells from patients responding to anti‐TNF antibody therapy. Adalimumab therapy, but not etanercept therapy, induces a potent and stable Treg cell population with the potential to restrain the progression of IL‐17–associated inflammation in RA via regulation of monocyte‐derived IL‐6.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.34565

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 162

Metadata

Authors
McGovern, J. L., Nguyen, D. X., Notley, C. A., Mauri, C., Isenberg, D. A., & Ehrenstein, M. R.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2012-09-28
Volume
64
Issue
10
Pages
3129-3138
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W1980564318
Cited by
162
References
4
FWCI
11.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Th17 cells are restrained by Treg cells via the inhibition of interleukin‐6 in patients with rheumatoid arthritis responding to anti–tumor necrosis factor antibody therapy. https://app.cochat.ai/papers/10.1002/art.34565
The paper
McGovern, J. L., Nguyen, D. X., Notley, C. A., Mauri, C., Isenberg, D. A., & Ehrenstein, M. R. (2012). Th17 cells are restrained by Treg cells via the inhibition of interleukin‐6 in patients with rheumatoid arthritis responding to anti–tumor necrosis factor antibody therapy. Arthritis & Rheumatism. https://doi.org/10.1002/art.34565

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.